C
CMPS
Compass Pathways Plc
12.00
+0.53+4.62%After Hours: 12.01 +0.01 +0.08%19:55 10/09 EDT
OPEN/PREV CLOSE11.69/11.47
TODAY RANGE11.42-12.08
VOL2.28M
MARKET CAP1.66B
52 WEEK RANGE4.880-15.87
AVG VOL (3M)3.01M
% TURNOVER1.54%
TURNOVER--
P/E (TTM)-3.4558
% RANGE5.71%
EPS(TTM)-3.4724
P/E(FORWARD)-5.5779
P/B19.27
BVPS0.6228
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.54B
SHARES OUTSTANDING138.48M
NEXT EARNINGS11/02-11/06
FREE FLOAT127.92M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·15h ago
How Phase 3 Depression Trial Results Will Impact Compass Pathways Stock
Simply Wall St·10/01 15:18
How Phase III Progress At Compass Pathways Stock Has Changed Its Investment Story
Simply Wall St·09/23 13:43
How Investors May Respond To Compass Pathways Stock 52 Week Depression Trial Results
TipRanks·09/21 17:56
H.C. Wainwright Sticks to Its Buy Rating for COMPASS Pathways (CMPS)
Simply Wall St·09/17 02:22
How Is COMPASS Pathways (CMPS) Shaping TRD Care Beyond Clinical Trial Results?
Simply Wall St·09/15 13:21
COMPASS Pathways (CMPS) Could Be 41% Undervalued On Phase 3 COMP360 Results
Simply Wall St·09/14 12:26
Learn Why The Bull Case For COMPASS Pathways (CMPS) Could Change Following One Year Trial Results
Simply Wall St·09/13 07:21
COMPASS Pathways (CMPS) Stock Looks Above Fair Value While Its 176% Return Stays Strong
TipRanks·09/11 20:15
Strata Mental Health Solutions awarded training grant by Compass Pathways
Simply Wall St·09/11 18:24
COMPASS Pathways (CMPS) Picks Five Groups For Provider Training Grants
TipRanks·09/10 14:50
Psychedelic: Optimi to initiate Phase 2 trial of psilocybin-assisted therapy
Simply Wall St·09/09 23:31
COMPASS Pathways (CMPS) Reports 52 Week Phase 3 COMP360 Trial Results